FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135098277> ?p ?o ?g. }

• W3135098277 abstract "Abstract Introduction Covid-19 is a triphasic disorder first typified by a viral phase that lasts from the first onset of symptoms until seven days later. This is followed by a second and third phase, initially characterized by the appearance of lung infiltrates, followed in 20% by respiratory failure. The second phase is usually heralded by an elevation of serologic inflammatory markers including CRP, ferritin, IL-6, LDH as well as D-dimers. Approximately 20% proceed to the second phase and are usually then treated with dexamethasone, provided they are oxygen-dependent since these are the only cases that benefit from dexamethasone. If we had objective criteria to predict this 20% that develop severe illness, they could preemptively be treated with steroids. In this exploratory study we investigated the early use of preemptive steroids in the setting of early disease, in high-risk non-oxygen dependent cases. Methods Eligible patients were those 21 years or older with a diagnosis of Covid-19 and oxygen saturation ≥91%. For patients to be classified as high-risk, they had to exhibit two or more of the following abnormalities 7-10 days after first symptom: IL-6 ≥ 10 pg/ml, ferritin > 500 ng/ml, D-dimer > 1 mg/L (1,000 ng/ml), CRP > 10 mg/dL (100 mg/L), LDH above normal range lymphopenia (absolute lymphocyte count <1,000 /µL), oxygen saturation between 91-94%, or CT chest with evidence of ground glass infiltrates. Primary endpoint was progression to respiratory failure. CALL score method was used to predict the expected number of cases of respiratory failure. High risk patients received methylprednisolone (MPS) 80 mg IV daily x 5 days starting no earlier than seven days from first onset of symptoms. The primary endpoint was progression to hypoxemic respiratory failure defined as PaO2 <60 mm Hg or oxygen saturation ≤90%. Secondary endpoints included survival at 28 days from registration, admission to intensive care and live discharge from the hospital. Change in levels of inflammatory markers and length of hospitalization were also assessed. Results In 76 patients, the expected number with respiratory failure was 30 (39.5%), yet only 4 (5.3%) developed that complication (p=.00001). Survival at 28 days was 98.6%. Improvement in inflammatory markers correlated with favorable outcome. Conclusions Our results are encouraging and suggest that this approach is both effective and safe." @default.
• W3135098277 created "2021-03-15" @default.
• W3135098277 creator A5003239953 @default.
• W3135098277 creator A5026070384 @default.
• W3135098277 creator A5026109465 @default.
• W3135098277 creator A5026190976 @default.
• W3135098277 creator A5028148008 @default.
• W3135098277 creator A5037057039 @default.
• W3135098277 creator A5046023120 @default.
• W3135098277 creator A5046871242 @default.
• W3135098277 creator A5079572710 @default.
• W3135098277 date "2021-03-09" @default.
• W3135098277 modified "2023-10-01" @default.
• W3135098277 title "Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19" @default.
• W3135098277 cites W2072351874 @default.
• W3135098277 cites W3005403371 @default.
• W3135098277 cites W3009885589 @default.
• W3135098277 cites W3010592738 @default.
• W3135098277 cites W3015305373 @default.
• W3135098277 cites W3025535414 @default.
• W3135098277 cites W3034961086 @default.
• W3135098277 cites W3035854673 @default.
• W3135098277 cites W3043642155 @default.
• W3135098277 cites W3045231518 @default.
• W3135098277 cites W3080079070 @default.
• W3135098277 cites W3084076173 @default.
• W3135098277 cites W3109092116 @default.
• W3135098277 cites W4255364305 @default.
• W3135098277 doi "https://doi.org/10.1101/2021.03.08.21253117" @default.
• W3135098277 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7987043" @default.
• W3135098277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33758884" @default.
• W3135098277 hasPublicationYear "2021" @default.
• W3135098277 type Work @default.
• W3135098277 sameAs 3135098277 @default.
• W3135098277 citedByCount "3" @default.
• W3135098277 countsByYear W31350982772022 @default.
• W3135098277 countsByYear W31350982772023 @default.
• W3135098277 crossrefType "posted-content" @default.
• W3135098277 hasAuthorship W3135098277A5003239953 @default.
• W3135098277 hasAuthorship W3135098277A5026070384 @default.
• W3135098277 hasAuthorship W3135098277A5026109465 @default.
• W3135098277 hasAuthorship W3135098277A5026190976 @default.
• W3135098277 hasAuthorship W3135098277A5028148008 @default.
• W3135098277 hasAuthorship W3135098277A5037057039 @default.
• W3135098277 hasAuthorship W3135098277A5046023120 @default.
• W3135098277 hasAuthorship W3135098277A5046871242 @default.
• W3135098277 hasAuthorship W3135098277A5079572710 @default.
• W3135098277 hasBestOaLocation W31350982771 @default.
• W3135098277 hasConcept C126322002 @default.
• W3135098277 hasConcept C203092338 @default.
• W3135098277 hasConcept C2778319317 @default.
• W3135098277 hasConcept C2780372218 @default.
• W3135098277 hasConcept C2780401358 @default.
• W3135098277 hasConcept C535046627 @default.
• W3135098277 hasConcept C71924100 @default.
• W3135098277 hasConcept C90924648 @default.
• W3135098277 hasConceptScore W3135098277C126322002 @default.
• W3135098277 hasConceptScore W3135098277C203092338 @default.
• W3135098277 hasConceptScore W3135098277C2778319317 @default.
• W3135098277 hasConceptScore W3135098277C2780372218 @default.
• W3135098277 hasConceptScore W3135098277C2780401358 @default.
• W3135098277 hasConceptScore W3135098277C535046627 @default.
• W3135098277 hasConceptScore W3135098277C71924100 @default.
• W3135098277 hasConceptScore W3135098277C90924648 @default.
• W3135098277 hasLocation W31350982771 @default.
• W3135098277 hasLocation W31350982772 @default.
• W3135098277 hasLocation W31350982773 @default.
• W3135098277 hasOpenAccess W3135098277 @default.
• W3135098277 hasPrimaryLocation W31350982771 @default.
• W3135098277 hasRelatedWork W1832107025 @default.
• W3135098277 hasRelatedWork W1990941510 @default.
• W3135098277 hasRelatedWork W2075483136 @default.
• W3135098277 hasRelatedWork W2153052119 @default.
• W3135098277 hasRelatedWork W2348125816 @default.
• W3135098277 hasRelatedWork W2353272152 @default.
• W3135098277 hasRelatedWork W2361968903 @default.
• W3135098277 hasRelatedWork W2415445890 @default.
• W3135098277 hasRelatedWork W2898490955 @default.
• W3135098277 hasRelatedWork W3029887057 @default.
• W3135098277 isParatext "false" @default.
• W3135098277 isRetracted "false" @default.
• W3135098277 magId "3135098277" @default.
• W3135098277 workType "article" @default.